Table 2:
Multivariate adjusted ORs for the risk of MACE.
| n (%) | OR (95% CI) | |||
|---|---|---|---|---|
| Cases | Controls | Adjusted | P-value | |
| No fibrate use | 15 274 (96.5) | 30 551 (96.5) | 1 (reference) | |
| Fibrate use | 556 (3.5) | 1109 (3.5) | 0.84 (0.75–0.94) | <.05 |
| Current use (within 90 days) | 225 (1.4) | 486 (1.5) | 0.81 (0.68–0.97) | <.05 |
| Recent use (91–365 days) | 71 (0.5) | 156 (0.5) | 0.65 (0.48–0.90) | <.05 |
| Past use (over 365 days) | 260 (1.6) | 467 (1.5) | 0.94 (0.79–1.12) | .49 |
Covariates list: age, sex, eGFR category, diabetes, atrial fibrillation/flutter, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, chronic pulmonary disease, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, β-blockers, calcium channel blockers, statins, diuretics, anticoagulants, antiplatelet agents, sodium-glucose cotransporter 2 inhibitor, glucagon-like peptide-1 receptor agonist, glucocorticoid inhalant, steroids, NSAIDs, opioids, antidepressant and calendar year of cohort entry.